| [1] |
YOU H, MA X, EFE C, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis[J]. Hepatol Int, 2022, 16(1): 1-23. DOI: 10.1007/s12072-021-10276-6. |
| [2] |
GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7. |
| [3] |
Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Hepatol, 2022, 38(1): 35-41. DOI: 10.3760/cma.j.cn112138-20211112-00794 |
| [4] |
SHIMOYAMA S, KAWATA K, OHTA K, et al. Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis[J]. Eur J Immunol, 2021, 51(6): 1519-1530. DOI: 10.1002/eji.202048589. |
| [5] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update[J]. J Hepatol, 2021, 75(3): 659-689. DOI: 10.1016/j.jhep.2021.05.025. |
| [6] |
ZENG Y, CHEN S, FU Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27(2): 143-155. DOI: 10.1111/jvh.13216. |
| [7] |
XIAO LY, XING AW, TAN SZ. Research advances in the association between liver failure and intestinal barrier injury[J]. J Clin Hepatol, 2021, 37(11): 2710-2714. DOI: 10.3969/j.issn.1001-5256.2021.11.049. |
| [8] |
GIORDANO DM, PINTO C, MARONI L, et al. Inflammation and the gut-liver axis in the pathophysiology of cholangiopathies[J]. Int J Mol Sci, 2018, 19(10): 3003. DOI: 10.3390/ijms19103003. |
| [9] |
MA HD, ZHAO ZB, MA WT, et al. Gut microbiota translocation promotes autoimmune cholangitis[J]. J Autoimmun, 2018, 95: 47-57. DOI: 10.1016/j.jaut.2018.09.010. |
| [10] |
LI Y, TANG R, LEUNG P, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases[J]. Autoimmun Rev, 2017, 16(9): 885-896. DOI: 10.1016/j.autrev.2017.07.002. |
| [11] |
GRAHAM JJ, MUKHERJEE S, YUKSEL M, et al. Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis[J]. Hepatology, 2022, 75(3): 518-530. DOI: 10.1002/hep.32193. |
| [12] |
LI B, SELMI C, TANG R, et al. The microbiome and autoimmunity: a paradigm from the gut-liver axis[J]. Cell Mol Immunol, 2018, 15(6): 595-609. DOI: 10.1038/cmi.2018.7. |
| [13] |
MORO-SIBILOT L, BLANC P, TAILLARDET M, et al. Mouse and human liver contain immunoglobulin a-secreting cells originating from peyer's patches and directed against intestinal antigens[J]. Gastroenterology, 2016, 151(2): 311-323. DOI: 10.1053/j.gastro.2016.04.014. |
| [14] |
LLEO A, LEUNG P, HIRSCHFIELD GM, et al. The pathogenesis of primary biliary cholangitis: A comprehensive review[J]. Semin Liver Dis, 2020, 40(1): 34-48. DOI: 10.1055/s-0039-1697617. |
| [15] |
YANG Y, CHOI J, CHEN Y, et al. E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants[J]. Hepatology, 2022, 75(2): 266-279. DOI: 10.1002/hep.32172. |
| [16] |
TANAKA A, LEUNG P, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195(1): 25-34. DOI: 10.1111/cei.13198. |
| [17] |
BERTOLINI A, FIOROTTO R, STRAZZABOSCO M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation[J]. Semin Immunopathol, 2022, 44(4): 547-564. DOI: 10.1007/s00281-022-00935-7. |
| [18] |
MAYO MJ. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?[J]. Hepatology, 2022, 76(2): 518-531. DOI: 10.1002/hep.32405. |
| [19] |
XIANG J, ZHANG Z, XIE H, et al. Effect of different bile acids on the intestine through enterohepatic circulation based on FXR[J]. Gut Microbes, 2021, 13(1): 1949095. DOI: 10.1080/19490976.2021.1949095. |
| [20] |
TANG R, WEI Y, LI Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3): 534-541. DOI: 10.1136/gutjnl-2016-313332. |
| [21] |
SUN L, CAI J, GONZALEZ FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 335-347. DOI: 10.1038/s41575-020-00404-2. |
| [22] |
LI B, ZHANG J, CHEN Y, et al. Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary cholangitis[J]. Gut Microbes, 2021, 13(1): 1946366. DOI: 10.1080/19490976.2021.1946366. |
| [23] |
CHEN W, WEI Y, XIONG A, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis[J]. Clin Rev Allergy Immunol, 2020, 58(1): 25-38. DOI: 10.1007/s12016-019-08731-2. |
| [24] |
SEHGAL R, BEDI O, TREHANPATI N. Role of microbiota in pathogenesis and management of viral hepatitis[J]. Front Cell Infect Microbiol, 2020, 10: 341. DOI: 10.3389/fcimb.2020.00341. |
| [25] |
MASLENNIKOV R, IVASHKIN V, EFREMOVA I, et al. Probiotics in hepatology: An update[J]. World J Hepatol, 2021, 13(9): 1154-1166. DOI: 10.4254/wjh.v13.i9.1154. |
| [26] |
FOLEY MH, O'FLAHERTY S, ALLEN G, et al. Lactobacillus bile salt hydrolase substrate specificity governs bacterial fitness and host colonization[J]. Proc Natl Acad Sci U S A, 2021, 118(6): e2017709118. DOI: 10.1073/pnas.2017709118. |
| [27] |
LIU Y, CHEN K, LI F, et al. Probiotic lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice[J]. Hepatology, 2020, 71(6): 2050-2066. DOI: 10.1002/hep.30975. |
| [28] |
QI JC, XING WJ, DU Y, et al. Effect of ursodeoxycholic acid and microecological agents on intestinal flora in patients with primary biliary cholangitis[J]. J Pract Hepatol, 2020, 23(4): 524-527. DOI: 10.3969/j.issn.1672-5069.2020.04.018. |
DownLoad: